Oruka Therapeutics Inc(ORKA) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Oct 27 at 4:16 PM ET (Korea 10/28 05:16)
Full metrics table
| Index | RUT | P/E | - | EPS (ttm) | -2.46 | Insider Own | 11.21% | Shs Outstand | 61.1M | Perf Week | 21.14% |
| Market Cap | 6.34B | Forward P/E | - | EPS next Y | -17.61% | Insider Trans | -34.98% | Shs Float | 58.8M | Perf Month | 13.8% |
| Enterprise Value | 5.48B | PEG | - | EPS next Q | -0.6 | Inst Own | 103.57% | Short Float | 10.4% | Perf Quarter | 8.79% |
| Income | -0.13B | P/S | - | EPS this Y | -29.96% | Inst Trans | 52.97% | Short Ratio | 6.81 | Perf Half Y | 29.49% |
| Sales | 0.00B | P/B | 5.26 | EPS next 5Y | -25.11% | ROA | -17.76% | Short Interest | 6.11M | Perf YTD | 216.1% |
| Book/sh | 18.2 | P/C | 7.26 | EPS past 3/5Y | 34.61% 37.79% | ROE | -18.23% | 52W High | -17.06% ($115.51) | Perf Year | 245.88% |
| Cash/sh | 13.19 | P/FCF | - | Sales past 3/5Y | - | ROIC | -11.9% | 52W Low | 279.75% ($25.23) | Perf 3Y | 693.87% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 32.27% | Gross Margin | - | Volatility(W/M) | 6.57% 5.44% | Perf 5Y | 470.98% |
| Dividend TTM | - | EV/Sales | - | Sales Y/Y TTM | - | Oper. Margin | - | ATR (14) | 4.93 | Perf 10Y | -65.64% |
| Dividend Ex-Date | - | Quick Ratio | 38.51 | EPS Q/Q | -12.26% | Profit Margin | - | RSI (14) | 66.15 | Recom | 1.07 |
| Dividend Gr. 3/5Y | - | Current Ratio | 38.51 | Sales Q/Q | - | SMA20 | 18.53% ($80.83) | Beta | -0.3 | Target Price | $152.23 |
| Payout | - | Debt/Eq | 0 | Earnings | 2026/8/10 | SMA50 | 7.37% ($89.23) | Rel Volume | 1.34 | Prev Close | $90.33 |
| Employees | 68 | LT Debt/Eq | 0 | EPS/Sales Surpr. | -7.32% - | SMA200 | 40.37% ($68.26) | Avg Volume(3M) | 0.90M | Price | $95.81 |
| IPO | 1997/8/8 | Option/Short | Yes/Yes | Trades | 13904 | Volume | 1,205,654 | Change | 6.07% |
🧬 This is a clinical-stage biotech company developing treatments for chronic skin diseases. The company is developing antibody therapies targeting chronic skin conditions such as plaque psoriasis, with a differentiated strategy focused on long-acting, extended-interval dosing formulations. It is a biotech firm specializing in therapeutics for inflammatory skin diseases.
Over the past 1 year, on the higher side
17% below its 1-year high.
Traded more than usual. That is 134% of its average volume.
ORKA has a sound balance sheet but weak earning power
Losses or thin margins. Early-stage growth or weakening competitiveness
Tap to view numbers
Growth has stalled
Earnings are expected to grow by -30.0% this year.
Tap to view numbers
Results came in about as expected
Mixed beats and misses
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have paid off
Bought 5 years ago, your return today would be +471.0%. The S&P 500 did +70% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Ownership is about average
Institutions hold 103.6%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
It ranks #41 of 594 in the industry
Based on market cap of $6B.
IOVA#39 Iovance Biotherapeutics Inc $7B PER - 
RYTM#40 Rhythm Pharmaceuticals Inc $6B PER - ORKA#41 Oruka Therapeutics Inc $6B PER - 
LGND#42 Ligand Pharmaceuticals Inc $6B PER 33.3 
IMVT#43 Immunovant Inc $6B PER - 
FAQ
What kind of company is ORKA?
ORKA belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of ORKA?
The market cap of ORKA is approximately $6.3B, ranking 1,197 within its sector.
What is the 52-week high and low for ORKA?
ORKA has recorded a 52-week high of $115.51 and a low of $25.23.
